Can a precise Lung-Sparing surgery beat standard lobectomy for early lung cancer?

NCT ID NCT07780591

Not yet recruiting ⭐️ CURE ⭐️ Sponsor: Shanghai Chest Hospital Source: ClinicalTrials.gov ↗

First seen Aug 21, 2026 · Last updated Aug 21, 2026

Summary

This trial is testing a surgical technique called septum-guided segmentectomy for people with early-stage (2-3 cm) non-small cell lung cancer. The surgery aims to remove only the diseased part of the lung, guided by natural anatomical landmarks, while preserving healthy tissue. The study will measure how well this approach controls cancer over three years and whether it helps maintain lung function compared to removing a larger portion of the lung.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: septum-guided anatomical segmentectomy (a lung-sparing surgical procedure)
What this could lead to: If successful, this could offer a less invasive surgical option for early-stage lung cancer that preserves more lung function while achieving similar cancer control.
What could go wrong: This is a single-center, single-arm trial, so results may not apply broadly. The surgery requires precise technique, and there is a risk of recurrence or complications, as with any lung surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.